Plasma p-tau217 assays effectively predict amyloid status but lack precision for tau staging in Alzheimer's disease.

No abstract is available for this paper.

• Publication year

  2026

• Venue

  Journal of Neurology

• Publication date

  2026-03-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/s00415-026-13726-zPMID 41784652
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Plasma p-tau217 and tau-PET predict future cognitive decline among cognitively unimpaired individuals: implications for clinical trials

  2025cited by this paper
• A Comprehensive Head-to-Head Comparison of Key Plasma Phosphorylated Tau 217 Biomarker Tests

  2024cited by this paper
• Revised criteria for diagnosis and staging of Alzheimer's disease: Alzheimer's Association Workgroup

  2024cited by this paper
• The ADNI PET Core at 20

  2024cited by this paper
• Acceptable performance of blood biomarker tests of amyloid pathology — recommendations from the Global CEO Initiative on Alzheimer’s Disease

  2024cited by this paper
• Clinical validation of the PrecivityAD2 blood test: A mass spectrometry‐based test with algorithm combining %p‐tau217 and Aβ42/40 ratio to identify presence of brain amyloid

  2024cited by this paper
• Comparison of two plasma p-tau217 assays to detect and monitor Alzheimer’s pathology

  2024cited by this paper
• Highly accurate blood test for Alzheimer’s disease is similar or superior to clinical cerebrospinal fluid tests

  2024cited by this paper
• Plasma N-terminal containing tau fragments (NTA-tau): a biomarker of tau deposition in Alzheimer’s Disease

  2024cited by this paper
• Diagnostic Accuracy of a Plasma Phosphorylated Tau 217 Immunoassay for Alzheimer Disease Pathology

  2024cited by this paper
• Plasma Phosphorylated Tau 217 and Aβ42/40 to Predict Early Brain Aβ Accumulation in People Without Cognitive Impairment

  2024cited by this paper
• CSF tau phosphorylation occupancies at T217 and T205 represent improved biomarkers of amyloid and tau pathology in Alzheimer’s disease

  2023cited by this paper
• Plasma Biomarker Strategy for Selecting Patients With Alzheimer Disease for Antiamyloid Immunotherapies.

  2023cited by this paper
• Plasma biomarkers predict Alzheimer’s disease before clinical onset in Chinese cohorts

  2023cited by this paper
• APOE effects on regional tau in preclinical Alzheimer’s disease

  2023cited by this paper
• Predicting amyloid PET and tau PET stages with plasma biomarkers

  2023cited by this paper
• Plasma p‐tau231 and p‐tau217 inform on tau tangles aggregation in cognitively impaired individuals

  2023cited by this paper
• Associations of the A/T/N profiles in PET, CSF, and plasma biomarkers with Alzheimer's disease neuropathology at autopsy

  2023cited by this paper
• Donanemab in Early Symptomatic Alzheimer Disease: The TRAILBLAZER-ALZ 2 Randomized Clinical Trial.

  2023cited by this paper
• Mitigating the Associations of Kidney Dysfunction With Blood Biomarkers of Alzheimer Disease by Using Phosphorylated Tau to Total Tau Ratios

  2023cited by this paper
• Appropriate Use Recommendations for Lecanemab

  2023cited by this paper
• Plasma and CSF biomarkers in a memory clinic: Head-to-head comparison of phosphorylated tau immunoassays

  2022cited by this paper
• Plasma biomarkers for Alzheimer’s Disease in relation to neuropathology and cognitive change

  2022cited by this paper
• Plasma Aβ42/40 ratio, p‐tau181, GFAP, and NfL across the Alzheimer's disease continuum: A cross‐sectional and longitudinal study in the AIBL cohort

  2022cited by this paper
• Tau positron emission tomography in preclinical Alzheimer's disease.

  2022cited by this paper
• Head-to-head comparison of 10 plasma phospho-tau assays in prodromal Alzheimer’s disease

  2022cited by this paper
• Association of Phosphorylated Tau Biomarkers With Amyloid Positron Emission Tomography vs Tau Positron Emission Tomography

  2022cited by this paper
• Direct Comparison of the Tau PET Tracers 18F-Flortaucipir and 18F-MK-6240 in Human Subjects

  2021cited by this paper
• Differences Between Plasma and Cerebrospinal Fluid Glial Fibrillary Acidic Protein Levels Across the Alzheimer Disease Continuum

  2021cited by this paper
• Using the Alzheimer's Disease Neuroimaging Initiative to improve early detection, diagnosis, and treatment of Alzheimer's disease

  2021cited by this paper
• Head-to-Head Comparison of 8 Plasma Amyloid-β 42/40 Assays in Alzheimer Disease

  2021cited by this paper
• Influence of common reference regions on regional tau patterns in cross-sectional and longitudinal [18F]-AV-1451 PET data

  2021cited by this paper
• Tau-PET and in vivo Braak-staging as prognostic markers of future cognitive decline in cognitively normal to demented individuals

  2021cited by this paper
• Plasma GFAP is an early marker of amyloid-β but not tau pathology in Alzheimer’s disease

  2021cited by this paper
• A multicentre validation study of the diagnostic value of plasma neurofilament light

  2021cited by this paper
• Validation of amyloid PET positivity thresholds in centiloids: a multisite PET study approach

  2021cited by this paper
• Association of Factors With Elevated Amyloid Burden in Clinically Normal Older Individuals.

  2020cited by this paper
• Longitudinal pathways of cerebrospinal fluid and positron emission tomography biomarkers of amyloid-β positivity

  2020cited by this paper
• Discriminative Accuracy of Plasma Phospho-tau217 for Alzheimer Disease vs Other Neurodegenerative Disorders.

  2020cited by this paper
• Functional brain architecture is associated with the rate of tau accumulation in Alzheimer’s disease

  2020cited by this paper
• Discriminative Accuracy of [18F]flortaucipir Positron Emission Tomography for Alzheimer Disease vs Other Neurodegenerative Disorders

  2018cited by this paper
• Comparison of multiple tau‐PET measures as biomarkers in aging and Alzheimer's disease

  2017cited by this paper
• PET Imaging of Tau Deposition in the Aging Human Brain.

  2016cited by this paper
• The Centiloid Project: Standardizing quantitative amyloid plaque estimation by PET

  2015cited by this paper
• Tau in physiology and pathology

  2015cited by this paper
• Tau pathology in Alzheimer disease and other tauopathies.

  2005cited by this paper

• No citing papers are available for this paper.